Tirzepatide beat semaglutide in the only head-to-head trial run so far. People on tirzepatide lost 20.2% of their body weight over 72 weeks, against 13.7% for semaglutide. That study finished before the strongest semaglutide dose reached the market, and the newest numbers put the two much closer together.
Our board-certified physicians prescribe both drugs and see what happens when a patient switches from one to the other. No trial tells you that part, which is why we wrote this comparison. Neither shot is sold over the counter, and both need a physician's supervision through the whole dose schedule. Here is what each drug is, what the trials found, how the side effects compare, and how to pick between them.
What Each Drug Is, in Plain Terms
Both copy gut hormones that tell your brain you are full. The difference is how many.
Semaglutide copies one hormone, GLP-1. It is sold as Wegovy for weight loss, as Ozempic for type 2 diabetes, and now as a daily pill in both of those brands. Novo Nordisk makes it.
Tirzepatide copies two hormones, GLP-1 and a second one called GIP. It is sold as Zepbound for weight loss and Mounjaro for type 2 diabetes, both as weekly shots only. Eli Lilly makes it.
That second hormone is the whole argument for tirzepatide. Hitting two targets instead of one appears to do more, and the trial numbers back that up.
Tirzepatide vs Semaglutide: Side-by-Side Comparison
What the Head-to-Head Trial Found
One trial has put these two drugs against each other directly. SURMOUNT-5 enrolled 751 adults with obesity and no diabetes across 32 sites in the United States and Puerto Rico, and ran for 72 weeks.
Everyone took the highest dose they could handle. For tirzepatide that meant 10 or 15 mg, and for semaglutide it meant 1.7 or 2.4 mg.
- Weight lost came to 20.2% on tirzepatide and 13.7% on semaglutide, a gap of 6.5 percentage points. In pounds, that is roughly 50 against 33.
- Waist size dropped 7.2 inches on tirzepatide and 5.1 inches on semaglutide. Waist measurements track deep belly fat, which matters most for heart and blood sugar health.
- People who quit over stomach side effects came to 2.7% on tirzepatide and 5.6% on semaglutide, so the drug that worked better was also the easier one to stay on.
Three things are worth knowing before you treat this as settled. Eli Lilly, which makes tirzepatide, paid for the trial. It was open-label, so everyone knew which drug they were getting. And men lost less weight than women on both drugs.
What Changed When the FDA Approved Semaglutide at 7.2 mg
SURMOUNT-5 tested semaglutide at 2.4 mg because that was the ceiling at the time. In March 2026, the FDA approved a 7.2 mg version called Wegovy HD, three times that dose.
In its own 72-week trial, Wegovy HD produced an average loss of 18.7% of body weight counting everyone who started, and 20.7% among people who stayed on treatment. About one in three of those who stayed on treatment lost a quarter of their body weight or more. Tirzepatide at 15 mg produced 20.9% and 22.5% on the same two measures over the same span.
Those two numbers came from separate studies with different participants, so nobody can call it a tie on that basis alone. What you can say is that the 6.5-point gap SURMOUNT-5 found no longer describes the strongest version of each drug. On these numbers it looks closer to two points.
Nobody has run the rematch yet. Until someone tests tirzepatide 15 mg against semaglutide 7.2 mg head-to-head, any claim that one is clearly stronger is running ahead of the evidence.
How the Side Effects Compare
Both drugs upset your stomach, and for the same reason. They slow how fast food leaves it.
The serious risks are the same for both. Each carries the FDA's strongest warning, about thyroid tumors seen in rodents, so nobody with a personal or family history of medullary thyroid cancer or MEN2 should take either. Pancreatitis, gallbladder problems, and kidney trouble from dehydration appear on both labels. Neither is safe in pregnancy.
Practical Differences That Do Not Show Up in Trial Results
Four things separate these drugs day to day, and none of them involve a percentage.
Semaglutide comes as a pill. A daily 25 mg Wegovy tablet was approved in December 2025 for weight loss, and Ozempic tablets, a renamed oral semaglutide for type 2 diabetes only, were approved in February 2026 and reached pharmacies in May 2026.
Birth control needs a backup on tirzepatide. The Zepbound label tells people on oral birth control to switch to a non-pill method, or add a barrier method, for four weeks after starting and after every dose increase. Semaglutide carries no such warning, since studies found it did not meaningfully change how the body absorbs the pill.
Tirzepatide takes longer to reach full strength. It climbs in 2.5 mg steps every four weeks and reaches 15 mg at week 21. Semaglutide reaches its 2.4 mg maintenance dose at week 17.
The bonus approvals differ. Tirzepatide is approved for moderate to severe sleep apnea in adults with obesity, the first drug ever cleared for that. Semaglutide is approved for lowering heart attack and stroke risk in people with heart disease, and for a liver condition called NASH with moderate to advanced scarring. If you have one of those conditions, your choice may already be made.
What They Cost
Both companies now sell directly to patients who pay cash, which changed the math for anyone whose insurance says no.
Skip compounded versions of either drug. The FDA declared the tirzepatide shortage over in December 2024 and the semaglutide shortage over in February 2025. Its temporary allowances for compounding copies of the brand-name drugs then ended between February and May 2025. Compounded versions are not FDA-approved, and the FDA does not review them for safety, quality or effectiveness.
Which One Should You Take?
Two readers, two different answers.
You Want the Biggest Result and Needles Are Fine
Tirzepatide is the reasonable first pick. It won the only head-to-head trial by a wide margin, fewer people quit it over side effects, and its top dose still comes out slightly ahead of Wegovy HD in separate trials (20.9% against 18.7%).
Wegovy HD is a fair alternative now that it exists, especially if your insurance covers semaglutide and not tirzepatide. Coverage decides this more often than biology does.
Have the sleep apnea conversation too. If you snore heavily, wake up tired, or have been told you stop breathing at night, say so. Tirzepatide's sleep apnea approval may get it covered when a weight-loss request would be refused.
Needles, Side Effects or Coverage Are Your Real Obstacle
Semaglutide has options tirzepatide does not. The daily pill removes injections from the equation entirely, and the 2.4 mg dose gives you a middle setting if the top dose is too much.
If heart disease is in your history, semaglutide's approval for lowering heart attack and stroke risk is worth raising with your doctor. The same goes for fatty liver disease with scarring.
If side effects drove you off one drug, switching to the other is reasonable and common. No washout period is required, though a one- to two-week break sometimes helps if the first drug hit you hard. You start at the lowest dose of the new drug either way.
What to Check Before You Start Either One
The same workup applies to both, and skipping it is how people end up on the wrong drug.
- Blood work first. A metabolic health assessment covering fasting blood sugar, HbA1c, insulin, thyroid and a lipid panel catches undiagnosed diabetes or prediabetes. That answer changes which drug fits and what insurance will approve.
- A medication review. Insulin and certain diabetes pills raise your risk of low blood sugar on either drug and often need lowering first.
- A coverage check before you fill anything. Finding out in week three that your plan excludes weight-loss drugs wastes a month.
- An eye exam if you have diabetic eye disease. Blood sugar dropping quickly can make it worse for a while.
Whichever you land on, the drug is one part of the plan. Medical weight loss programs and injections that add food guidance, strength training and regular check-ins give you results that outlast the last shot. Physician-supervised semaglutide injections for weight loss start from your lab results rather than a BMI number.
Frequently Asked Questions
Can you switch from semaglutide to tirzepatide?
Yes, and plenty of people do. You do not need a washout period, though a one- to two-week gap can help if the first drug caused rough side effects. You start the new drug at its lowest dose no matter what you were taking before.
Does tirzepatide work if semaglutide did not?
Often, yes. Research on people switching from a GLP-1 drug to tirzepatide found greater weight loss overall, though about one in eight developed new stomach side effects. Response varies enough that a poor result on one is not a prediction for the other.
Which one is better for type 2 diabetes?
Tirzepatide generally lowers blood sugar more. Semaglutide has the longer track record and carries approvals for reducing heart and kidney risk in people with diabetes, which tirzepatide does not. Your other conditions usually decide it.
Do you have to take these forever?
Plan on long-term treatment. Both work only while they are in your system, and appetite comes back within weeks of the last dose. Stopping is a conversation to plan with your doctor, not something to do abruptly.
Is one safer than the other?
Neither has a clear safety edge. They carry the same boxed warning, the same major risks, and the same list of people who should avoid them. The differences are in tolerability, which varies by person, and in the birth control interaction specific to tirzepatide.
Getting Help Choosing in Southern California
Picking between these two comes down to your lab results, your other conditions, what your insurance covers, and how your body handles the first few doses. A doctor who reviews all four can answer it in one visit.
Unify Care's board-certified doctors handle that evaluation and manage treatment from the first dose through every adjustment, with home visits and 24/7 telehealth access. More than 500 families across Southern California use the practice's concierge medicine in Orange County model, with house calls reaching Los Angeles, Riverside, Palm Springs, San Bernardino and San Diego. Reach out to the team to book a visit.
Sources
- Aronne LJ, et al. Tirzepatide as Compared With Semaglutide for the Treatment of Obesity (SURMOUNT-5). New England Journal of Medicine, 2025. https://www.nejm.org/doi/abs/10.1056/NEJMoa2416394
- American College of Cardiology. SURMOUNT-5: Greater Loss of Weight, Waist Circumference With Tirzepatide Than Semaglutide, July 2025. https://www.acc.org/Latest-in-Cardiology/Journal-Scans/2025/07/10/09/09/SURMOUNT-5
- U.S. Food and Drug Administration. Zepbound (tirzepatide) Prescribing Information, revised January 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf
- U.S. Food and Drug Administration. Wegovy (semaglutide) Prescribing Information, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s033lbl.pdf
- U.S. Food and Drug Administration. Ozempic (semaglutide) Prescribing Information, revised October 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s035,209637s037lbl.pdf
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
- Novo Nordisk. Wegovy HD (semaglutide 7.2 mg) Approved in the US, Providing 20.7% Mean Weight Loss, March 2026. https://www.biospace.com/press-releases/novo-nordisk-a-s-wegovy-hd-semaglutide-7-2-mg-approved-in-the-us-providing-20-7-mean-weight-loss
- Healio. FDA Approves High-Dose Wegovy 7.2 mg for Adults With Obesity, March 2026. https://www.healio.com/news/endocrinology/20260319/fda-approves-highdose-wegovy-72-mg-for-adults-with-obesity
- U.S. Food and Drug Administration. FDA Approves First Medication for Obstructive Sleep Apnea, December 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea
- Novo Nordisk. Wegovy Approved by FDA for the Treatment of Adults With Noncirrhotic MASH With Moderate to Advanced Liver Fibrosis, August 2025. https://www.prnewswire.com/news-releases/wegovy-approved-by-fda-for-the-treatment-of-adults-with-noncirrhotic-mash-with-moderate-to-advanced-liver-fibrosis-302531394.html
- Eli Lilly. Zepbound Savings and Insurance Options. https://zepbound.lilly.com/savings
- NovoCare. Get Your GLP-1 Medications Delivered With NovoCare Pharmacy. https://www.novocare.com/pharmacy.html
- Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge. https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
- Obesity Medicine Association. Tirzepatide vs Semaglutide: A Comprehensive Comparison for Providers, August 2026. https://obesitymedicine.org/blog/tirzepatide-vs-semaglutide
